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ABSTRACT 
Prostaglandin F2α is commonly administered to manipulate the estrous cycle in mares, at 
a  dosage of dinoprost tromethamine (Lutalyse®) at 10 mg, administered IM. My 
objectives were to compare three serial low-dose PGF2α protocols, and determine the 
most effective treatment in terms of number of injections, intensity of protocol, time 
allocated, and labor. Quarter Horse mares (n=11) were used in a crossover design. 
Lutalyse was administered at 1.1 mL per injection: treatment 1- PGF2α once 6d post-
ovulation; treatment 2- PGF2α twice daily 0 d, 1 d, and 2 d, then once 3 d and 4 d post- 
ovulation; treatment 3- PGF2α twice daily on 2 d, then once 3 d and 4 d post- ovulation. 
Teasing scores were assigned daily. Rectal palpation and ultrasound were performed to 
measure follicular growth and detect ovulation. Blood samples were drawn on 3 d and 6 d 
post-ovulation to analyze plasma progesterone (P4) levels. One-way ANOVA and Tukey 
Method Pairwise Comparisons were used for data analysis. Between treatments on 3 d 
and 6 d post-ovulation, plasma P4 values were not statistically different. Mean intervals 
from ovulation to ovulation for treatments 1, 2, and 3 were 14.8 d ± 3.1, 12.9 d ± 6.3 d 
and 14.3 d ± 1.4 respectively. Mean intervals from first day of treatment to ovulation 
were 9.8 d ± 2.0, 12.9 d ± 6.3, and 12.6 d ±1.7. Results did not show significant statistical 
difference. Further research is needed on low-dose administration of PGF2α. 
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 1 
INTRODUCTION 
 
Justification of the Study 
The equine industry in the United States has an economic impact of 
approximately $102 billion, a number recorded in 2005 and since increasing. With over 
1.4 million full-time jobs supported by the equine industry and over 9 million horses in 
the United States, the equine industry is a diverse and powerful substructure of the 
American economy (American Horse Council, 2017). 
Manipulation and control of the estrous cycle of mares is critical to the prosperity 
and vitality of the equine industry. Implemented estrous and ovulation synchronization 
protocols allow industry professionals to coordinate and allocate time, money, and 
resources to maximize success during the breeding season, and ultimately pregnancy 
rates in mares.  
When estrus and ovulations are synchronized, artificial insemination practices can 
be managed, or natural breeding can be planned efficiently for maximization of each 
stallion. Estrous synchronization allows embryo transfer and cloning processes to come 
to fruition with as little disturbance as possible (Klug and Jöchle, 2001).  
Administration of Prostaglandin F2α (PGF2α) is reportedly the most common 
method of estrus synchronization in the mare (Coffman and Pinto, 2016). Clinical uses of 
PGF2α include estrous synchronization, treatment for persistent CL syndrome, short-
cycling, and the termination of unwanted pregnancies (Burden et al., 2015). In the 
1970’s, research identified PGF2α as an endogenous luteolysin. The administration of 
exogenous PGF2α is widely accepted as an effective method of inducing luteolysis in 
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order to synchronize the estrous cycle (Coffman and Pinto, 2016). The induction of 
luteolysis is critical to the success of the reproductive management of the mare (Kuhl et 
al., 2016a). 
A more comprehensive understanding of the effects of various dosage protocols 
of exogenous prostaglandin given to cycling mares will allow advancement and success 
in regards to reproductive success of the mare.  
 
Statement of Purpose and Objectives of the Study  
The purpose of this study was to determine if a new treatment protocol would 
hasten the return to estrus and ovulation in cycling mares. Three serial low-dose PGF2α 
treatment protocols were compared in terms of total injections and intensity of protocol, 
in relation to efficacy of treatment. Results from this study may provide insight into low-
dose hormonal manipulation of the estrous cycle, to be implemented into new breeding 
management practices.   
The objective of the study was to determine the efficacy of serial low-dose 
administration of PGF2α designed to prevent luteal development and shorten the interval 
to ovulation in cycling mares.  
 
Hypotheses  
This study was designed around two hypotheses, as follows: 
1. Low-dose serial administration of PGF2α will not be as effective at inducing 
luteolysis and shortening the intraovulatory period or preventing development of 
the CL as the standard dosage rate for dinoprost tromethamine (Lutalyse®) in 
mares. 
 
2. There will be no difference in efficacy between treatment protocols.  
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LITERATURE REVIEW 
 
Overview of the Estrous Cycle 
Cyclicity of the mare is characterized by seasonal polyestrous; there are periods 
during the year in which most mares do not cycle regularly. Mares are long-day breeders, 
becoming the most reproductively receptive in the spring and into the summer (Senger, 
2012). Regulation of gonadotropin releasing hormone (GnRH) secretion is dependent on 
photoperiod. When the photoperiod is short, the pineal gland secretes melatonin, which 
downregulates GnRH production in the hypothalamus. When the photoperiod increases, 
melatonin production decreases, allowing GnRH to stimulate the release of FSH and LH. 
(Blanchard et al., 2003).  
Research has suggested that leptin and kisspeptin may have a direct effect on 
GnRH neurons in the hypothalamus. Adipocytes secrete leptin, a hormonal peptide, in 
relation to the fat content in the body. Leptin may be critical to the hypothalamic 
signaling that the animal is at an acceptable nutritional status for reproductive 
performance. Additionally, kisspeptin signaling supplies GnRH cell bodies in the 
hypothalamus. In response to leptin, kisspeptin neuron activity may be stimulated, which 
in turn stimulated GnRH neurons (Senger, 2012). 
Gonadotropin releasing hormone is secreted in the hypothalamus and released 
into the hypothalamic-pituitary portal system. In the anterior pituitary, GnRH then 
stimulates the production and secretion of follicle-stimulating hormone (FSH) and 
luteinizing hormone (LH). When estrogen is high and progesterone is low, LH secretion 
increases. Progesterone (P4) levels increase in the luteal phase as the CL continues to 
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develop. Once progesterone levels are above 2 ng/mL, behavioral signs of estrus are not 
seen in most mares. Ovulation is typically characterized by signs of estrus and plasma 
progesterone concentrations measuring 1 ng/mL or less. However, ovulation can occur 
without estrus, referred to as silent heat; low P4 levels allow the subsequent surge of LH 
and thus ovulation. The largest follicle is normally the one to ovulate; complete ovulation 
occurs in 2 to 7 minutes following the onset (Blanchard et al., 2003).  
The average estrous cycle of the mare is 21 days long. Estrus typically lasts 7 
days in mares. After the onset of estrus, ovulation occurs in approximately 5 days. After 
the LH surge, ovulation should be expected within 2 days (Senger, 2012). The estrous 
cycle is characterized by two distinct phases- the follicular phase and the luteal phase. 
The follicular phase occurs from the time the CL regresses, to the time of ovulation. 
Large antral follicles develop during the follicular phase, one of which will become 
dominant and later ovulate. Estradiol is secreted by the follicles, and is highest during the 
follicular phase. During the luteal phase, the CL develops, which creates an increase in 
progesterone levels. Follicular growth and development occurs during proestrus, along 
with secretion of estradiol. During estrus, estradiol secretion reaches its peak, and the 
mare becomes sexually receptive to the male. Progesterone secretion begins during 
metestrus, as CL formation begins, and progesterone secretion is then sustained during 
the diestrus period of the estrous cycle (Mottershead 2001; Figures 1 and 2).  
During the estrous cycle, follicular development occurs in a wave-like pattern. 
Several large follicles develop during a major follicular wave; one follicle will continue 
growth as the dominant follicle while smaller follicles will undergo atresia. The dominant 
follicle secretes hormones which inhibit FSH, which in turn halts growth of the non-
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dominant follicles (Shirazi et al., 2002). Proestrus and estrus both occur during the 
follicular phase of the estrous cycle, while metestrus and diestrus both occur during the 
luteal phase of the estrous cycle. The follicular phase accounts for approximately 20% of 
the estrous cycle. In turn, 80% of the estrous cycle is the luteal phase (Senger, 2012).  
 
Biochemistry of Progesterone 
Progesterone is a steroid hormone synthesized from cholesterol. Cholesterol can 
either be synthesized in the smooth endoplasmic reticulum via de novo synthesis, or 
synthesized in the liver from acetate and released into the bloodstream in lipid droplets. 
Pregnenolone, a 21-carbon intermediate, is produced via side-chain hydrolysis of 
cholesterol. 3ß-hydroxy-∆5-steroid dehydrogenase then converts pregnenolone to 
progesterone. Progesterone can later be converted to estrogens, androgens, or 
corticosteroids (McKinnon and Voss, 1993).  
Thecal cells produce 3ß-hydroxy-∆5-steroid dehydrogenase needed for the 
conversion of pregnenolone to progesterone; progesterone can then be converted to 
estradiol in the granulosa cells (Rotstein, 2016). The CL is the primary location of 
progesterone secretion (McKinnon and Voss, 1993). See Figure 3 for an overview in 
changes of plasma progesterone concentrations throughout the estrous cycle.  
 
Biochemistry of Prostaglandins 
Eicosanoids act at low concentrations, and are critical to reproduction. 
Eicosanoids do not transport through the bloodstream to their target tissue, but tend to act 
closer to the cells of production (Voet et al., 1999). Prostaglandins are classified as 
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eicosanoids, comprised of modified long-chain fatty acids with 20 carbon atoms. 
Prostaglandin synthases are used in the cyclooxygenase pathway to synthesize 
prostaglandins from arachidonic acid, which becomes available when phospholipids of 
the cell membrane are hydrolyzed. The phospholipid degradation is quickened in the 
presence of phospholipase A, which serves a catalytic role (Coffman and Pinto, 2016). 
PGF2α stimulates cyclooxygenase (COX)-2 mRNA expression in not only epithelial cells, 
but also in stromal cells. Low dose administration of PGF2α can increase COX-2 
expression, in turn inducing luteolysis. The increase in COX-2 expression leads to auto-
amplification of endometrial PGF2α production (Okuda et al., 2014). 
Prostaglandin F2α and prostaglandin E2 (PGE2) are the two main prostaglandins 
associated with reproduction in the mare. Endogenous prostaglandins are not only 
metabolized in the target tissue, but also in the lungs, kidneys, and liver. In mares, PGF2 
is metabolized to 15-keto- PGF2α, then 13,14-dihydro-15-keto- PGF2α, then 11-
ketotetranor-PGF compounds. The 13,14-dihydro-15-keto metabolite is more stable when 
separated from red blood cells in either plasma or serum, despite its 5 minute half-life. 
Therefore, prostaglandin F2α metabolite (PGFM) concentrations can be measured from 
peripheral blood in order to estimate the amount and rate that PGF2α is released from 
tissues at (McKinnon and Voss, 1993).  
 
Role of Prostaglandin in the Estrous Cycle  
Prostaglandin F2α is known as the main luteolysin, which is secreted from the 
endometrium. Prostaglandin F2α and progesterone metabolite concentrations can be 
measured by enzyme immunoassay profiles. When cloprostenol treatment effect on 
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cycling mares was analyzed, no cross reaction between progesterone and PGFM was 
demonstrated. Two hours post-treatment, progesterone decreased 50% and by 90% 24 
hours post-treatment. An increase in PGFM peaked at 45 minutes post-treatment, then 
decreased before again increasing at 16 hours post-treatment to the same level as the 45 
minute post-treatment level (Okuda et al., 2014). Studies have shown that the ovulatory 
effect of PGF2α not only occurs at the follicular level, but also in the central nervous 
system at the hypothalamus-hypophysis axis. Following PGF2α administration, FSH and 
LH levels in peripheral blood increase followed by an increase in GnRH (Newcombe et 
al., 2008).  
During luteolysis, oxytocin may be the main inductor of pulsatile secretions of 
PGF2α from the uterus. Prostaglandins are synthesized actively in the equine CL and may 
serve a critical role in its auto-paracrine regulation (Lukasik et al., 2014). Concentrations 
PGF2α and PGE2 were recording throughout the luteal phase, as well as mRNA 
transcription of PG synthesis enzymes found in the equine CL. Plasma progesterone 
levels, follicular diameter, and morphological appearance of the CL were all used to 
classify luteal structures. PGF2α and PGE2 levels were lowest in the mid-development of 
the CL (P<0.05), and the highest during the early-development CL (P<0.05). 
Prostaglandin-endoperoxide synthase 2 (PTGS-2) and synthase prostaglandin E (PGES) 
synthesis via mRNA transcription were measured highest in the early-development CL 
(P<0.05). In a second experiment, PGF2α and PGE2 stimulated mRNA transcription of 
PTGS-2, PGES, OXT receptor (OXTR), and 3ß-hydroxysteroid dehydrogenase (3βHSD) 
enzymes, while simultaneously stimulating progesterone and oxytocin secretion (P<0.05) 
(Lukasik et al., 2014). 
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Administration of PGF2α 
During the 1970’s and 1980’s, various PGF2α analogues were tested and 
developed for potential use in the livestock industry. Prostalene and fenprostalene, alpha-
chain allenic analogs, as well as fluprostenol were developed; fluprostenol being a 
synthetic PGF2α analog similar to cloprostenol. Luprostiol, a synthetic PGF2α analogue, is 
not approved for use in the United States but is available in certain European countries 
(Coffman and Pinto, 2016).  
Dinoprost tromethamine, the natural analogue of PGF2α, is the only form of PGF2α 
that has received approval by the FDA in the United States (Lutalyse; Pfizer Animal 
Health). Dinoprost tromethamine is a tham salt; naturally occurring in the PGF2α 
molecule. 1.34 mg of dinoprost is equal to 1 mg of PGF2α free acid. The labeled dosage 
of dinoprost is 10 mg per mare, although studies have shown significantly smaller doses 
to have high efficacy rates as well. A single injection of 1.25 mg dinoprost can be 
effective when administered between days 6 and 12 following ovulation. Lutalyse is 
diluted to 5 mg/mL, therefore administration does not require dilution. Doses as low as 
1.1 ug/kg have been reported as having an affect on luteal function, but this dose may not 
result in complete luteolysis. After administration of 5 mg PGF2α IV, plasma clearance 
was 3.3 ± 0.5 L/hr/kg, half- life was 1.57 ± 0.26 minutes, elimination half- life was 25.9 ± 
5.0 minutes, and maximum plasma PGF2α concentration was 249.1 ± 36.8 ng/mL 
(Coffman and Pinto, 2016).  
Closprostenol is a synthetic analogue of PGF2α which is commonly used by 
industry professionals to shorten the interval to ovulation, due to its longer half-life than 
dinoprost. Additionally, there are fewer side effects associated with cloprostenol. The 
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pharmokinetic parameters of cloprostenol in horses have not been published. There are 
two enantiomers of cloprostenol available; d-cloprostenol and l-cloprostenol. 
Recommended dosage rates for cloprostenol are noticeably smaller than the 
recommended dosage rates of dinoprost. The d-enantiomer is pharmacologically active 
and luteolytic, therefore the dosage needed to induce luteolysis is much lower than the 
luteolytic dose of d,l-cloprostenol. Estrumate, produced by Merck Animal Health, is a 
commonly used racemic mixture of d,l-cloprostenol sodium administered at a dosage rate 
of 250 to 500 µg per mare. In other countries, the active d-cloprostenol enantiomer is 
used in order to prepare stronger solutions of cloprostenol, though not available in the 
United States (Coffman and Pinto, 2016).  
To shorten the luteal phase of the estrous cycle, PGF2α can be administered 
subcutaneously or intramuscularly to induce luteolysis. Mares treated with PGF2α 
typically display estrus anywhere from 2 to 5 days post-treatment, and ovulate 7 to 10 
days post-treatment. However, if a large follicle is present at the time of PGF2α 
administration, mares may ovulate as soon as 48-72 hours following treatment with 
PGF2α (Coffman and Pinto, 2016). In mares with a confirmed fully functional CL, PGF2α 
has approximately an 80% luteolytic rate when given as a single dose to mares 5 days 
post-ovulation. Following PGF2α treatment, progesterone levels decrease drastically, and 
the CL undergoes lysis. Endometrial edema will develop, and the interovulatory interval 
will also decrease. The interovulatory interval is also decreased when partial luteolysis 
occurs. However, no endometrial edema will develop, which may increase the incidence 
of silent heat (Newcome and Cuervo-Arango, 2014).   
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If an atretic or small preovulatory follicle is present at the time of PGF2α 
treatment, the interval from treatment to ovulation may be as long as 15 days. A single 
dose of PGF2α given during the early (0-4 days post-ovulation) diestrus period did not 
induce luteolysis. Following the trials, the conclusion was drawn that the equine CL is 
not fully responsive to the luteolytic actions of PGF2α until the CL is, at minimum, 5 days 
old (Coffman and Pinto, 2016).  
Cloprostenol can decrease the time needed for follicular maturation, lysis of the 
CL, and ovulation in mares. Efficacy of treatment was dependent on the dose of 
cloprostenol administered. For each treatment group, the interval to ovulation decreased 
as the size of the pre-ovulatory follicle at time of treatment increased. A synergistic 
relationship was present between follicular diameter and dose efficacy (Newcombe et al., 
2008). The dose of cloprostenol administered to each mare effects the interval to 
ovulation; hence the use of cloprostenol may be a method of more precisely controlling 
the estrous cycle, as well as the time of ovulation, in the mare (Newcombe et al., 2008).  
When compared to cloprostenol, a larger number of mares ovulated within 48 
hours of hCG administration when given luprostiol (P<0.01). Additionally, mares given 
luprostiol displayed a shorter interval from hCG treatment to ovulation (P<0.01). 
However, no difference was shown in the interval from estrus to hCG treatment, or the 
interval from estrus to ovulation. Preovulatory follicles in both treatment groups 
measured smaller at the time ovulation was induced when compared to the control group 
(Kuhl et al., 2016a).  
The rate of double ovulations was not significantly impacted in mares treated with 
either luprostiol or cloprostenol. Furthermore, fertility and pregnancy rates were not 
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affected by administration of PGF2α analogs luprostiol or cloprostenol.  In 2016, the 
interval from PGF2α administration to ovulation showed less variation using luprostiol 
rather than cloprostenol, when given to mares in the luteal phase of the estrous cycle 
(Kuhl et al., 2016a).  
When PGF2α was given in the early post-ovulatory period, luteal function was 
inhibited, due to low levels of plasma progesterone. Inhibition of luteal function should 
induce the return to estrus and ovulation, followed by a normal diestrus period of the 
estrous cycle. Subsequently, mares treated with PGF2α during the study were expected to 
conceive at normal fertility rates when artificially inseminated following treatment. 
PGF2α is an efficient way of inhibiting luteal function, or promoting anti-luteogenesis. In 
this study, no effect of PGF2α treatment on fertility rate was found in the estrus period 
following treatment (Pinto et al., 2014).  
When administered to mares with a 28 mm or larger follicle, ovulation may occur 
in less than 4 days; concerns have surfaced that PGF2α may alter the fertility of those 
manipulated cycles. When evaluating the effect of the interval from PGF2α treatment to 
ovulation on embryo recovery rates, as well as pregnancy rates in mares, the interval 
from treatment to ovulation (ITO) was found to have a significant (P=0.01) effect on the 
embryo recovery rate (ERR) in the mares, with the highest ERR recorded for the mares 
with an ITO of 6 to 10 days. Additionally, the ERR in mares with an ITO of less than 6 
days was reduced, when compared to the ERR of mares with a longer ITO. In this study, 
no association was found between ITO and pregnancy rate (Pietrani et al., 2016). 
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PGF2α Synchronization Protocols 
As reviewed by Coffman and Pinto (2016), Douglas and Ginther conducted an 
early study, with mares administered either 1.25, 2.5, 5.0, or 10.0 mg of PGF2α 
intramuscularly (IM) 6 days after ovulation. All mares displayed shorter diestrus and 
interovulatory intervals, when compared to control mares that were not treated with 
PGF2α. In subsequent trials, some mares underwent complete luteolysis 3 days after 
ovulation, though this is not a reliable measure of the efficacy of synchronization 
utilizing PGF2α injections. Recommendations to administer PGF2α 5 days after ovulation 
were implemented following the study. When the date of ovulation is unknown, PGF2α 
treatments should be repeated for 2-3 days to minimize the risk of CL resurgence 
(Coffman and Pinto, 2016).  
In 1974, research revealed the ability of PGF2α to induce partial luteolysis, 
followed by a subsequent resurgence of a functional CL. Two mares were given a low 
dose of PGF2α 9 days after ovulation, with plasma progesterone decreasing approximately 
12 hours post-treatment. However, a rise in progesterone levels was noted at 48 hours 
post-treatment (Coffman and Pinto, 2016). In a 2014 study, mares given between 4 and 
13 treatments of PGF2α at a dosage rate of 37.5 µg of d-cloprostenol per injection 
displayed a significant decrease in the percentage of mares which underwent full 
luteolysis (P<0.01). Data analysis suggested that the number of treatments received, as 
well as the length of treatment could both factor into the decreased luteolytic response in 
the mares. PGF2α receptors on the CL may be physiologically inclined to abnormal 
luteolysis when under the influence of more intensive PGF2α treatment plans. Following 
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treatment, the number of mares with a longer diestrus period also increased (Newcombe 
and Cuervo-Arango, 2014).  
A common assumption in the equine breeding industry is that the early CL is not 
responsive to luteolytic actions of PGF2α administration. Repeated PGF2α treatment 
during the early diestrus period may produce a similar return to estrus to those mares 
administered a single PGF2α injection during the mid-diestrus period of the estrous cycle. 
Additionally, fertility of the early diestrus induced mares was hypothesized by Coffman 
et al. (2014) to not differ from those mares treated conventionally with one injection. In 
group 1, mares were given a single 10 mg (2.0 mL) dose of dinoprost tromethamine on 
day 10 post-ovulation. In group 2, mares were administered 10 mg PGF2α twice daily on 
days 0, 1, and 2, then given 10 mg PGF2α once daily on days 3 and 4 post-ovulation. 
Once a 35 mm or larger follicle was detected, mares in estrus were artificially 
inseminated with a minimum insemination dose of 2 billion motile sperm. Pregnancy was 
then determined after a growing embryonic vesicle was detected on 2 consecutive 
examinations, 14 days post-ovulation (Coffman et al., 2014).  
In group 1 mares, Coffman et al. (2014) concluded that luteolysis occurred within 
48 hours of treatment. When PGF2α is administered at a higher frequency during early 
diestrus, the antiluteogenic effects are similar to those seen when a single injection is 
given in the mid-diestrus period of the cycle. In group 2, the treatments given on days 3 
and 4 prevented luteal resurgence and prolonged luteal formation, in turn increasing the 
response rate of the treatment group. Luteal cells are responsive to PGF2α, almost 
immediately following ovulation. The diestrus period of the cycle was shortened for 
mares administered PGF2α in both the early and mid-diestrus phases of the estrous cycle. 
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PGF2α administration during early diestrus provided a shorter interval to ovulation when 
compared to the mares given PGF2α during the mid-luteal phase (Coffman et al., 2014).  
 
Synchronization of Estrus in Other Livestock Species 
The ovarian anatomy of the mare displays distinct differences from the bovine 
ovarian anatomy. The cortex and medulla of the ovary are reverse of what is seen in 
cattle; the cortex is located inside the ovary. While ovulation occurs from various 
locations of the bovine CL, ovulation only occurs at the ovulation fossa in the mare. 
Additionally when rectal palpation is performed in the mare, follicles may be palpated 
but the CL is not easily palpated manually because of its location in the ovarian medulla 
(Senger 2012).  
The equine CL is 18-fold more sensitive to PGF2α than the bovine CL. The equine 
luteal cell membrane has a 10-time greater affinity for PGF2α when compared to the 
bovine cell membrane. The higher sensitivity of the equine CL to PGF2α may be 
attributed to the strong binding affinity of PGF2α to the CL, as well as the slower 
metabolic passage rate in mares (Coffman and Pinto, 2016). In cattle, PGF2α metabolite 
peaks are followed by an increase in progesterone concentrations every 8 hours. 
Progesterone will increase until reaching the pre- PGFM pulse concentration (Ginther 
and Santos, 2015).  
In cattle treated with a PGF2α analog, nitric oxide metabolites may be detected in 
an ovarian vein sooner than detected in a jugular vein. Because of the earlier detection in 
the ovarian vein, changes in the systemic concentration of nitric oxide metabolites can be 
utilized in order to identify nitric oxide production changes in the ovary. Research in 
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heifers has suggested that LH is critical for the systemic increase in nitric oxide 
metabolites, which is associated with a simulated PGFM pulse (Ginther et al., 2015).  
Similar to what has been done with cattle and sheep, nitric oxide metabolite 
plasma concentrations were collected from equine jugular veins in order to measure nitric 
oxide metabolite output. The measured changes in jugular plasma nitric oxide metabolite 
concentration were, in this study, associated with a PGFM pulse, although only at a 
certain stage of luteolysis. Although this study did not find the CL to be the primary 
source of nitric oxide production, nitric oxide production during luteolysis may be 
analyzed by researching the nitric oxide metabolite concentration within the general 
circulation of the equine system (Ginther et al., 2015). 
 
Anovulatory Follicles  
Hormonal treatment with PGF2α may increase the risk of either double ovulations 
or anovulatory follicles. In order to determine the frequency of double ovulations and 
anovulatory follicles occurring in cycling mares treated with PGF2α, mares were given 5 
mg PGF2α at 10 days post-ovulation. Transrectal ultrasounds were performed every 2 
days until a 25 mm follicle was detected, then once every day until determination of 
ovulation. Double ovulations occurred in 15% more cycles within the treatment group 
when compared to the control group, which was not treated with PGF2α. The frequency of 
either a double ovulation or a single ovulation in concurrence with an anovulatory follicle 
was 6 times greater in the treatment group when compared to the control. (Ginther and 
Al-Mamun, 2009). 
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The occurrence of hemorrhagic anovulatory follicles following cloprostenol 
administration has been evaluated for its impact on the interval to ovulation in mares 
(Burden et al., 2015). Mares in the study were given a single IM injection of 250 μg 
cloprostenol, at varying times between days 5 and 12 post-ovulation. The average interval 
from treatment to ovulation recorded for the study was 8.4 + 2.5 days (P < 0.05). An 
inverse relationship between the interval from treatment to ovulation and the diameter of 
the largest follicle at time of treatment was observed. Three different treatment outcomes 
were observed: ovulation within 48 hours post-treatment (13.4%) with varying levels of 
uterine edema, ovulation after 48 hours post-treatment (73.1%) with larger uterine edema, 
or follicular regression without ovulation (13.4%), with a new dominant follicle 
eventually developing. Both age of the mare as well as season had no effect on the 
interval from treatment to ovulation. Development of hemorrhagic anovulatory follicles 
was low overall, at 2.5% (Burden et al., 2015).  
Uterine pathology and decreased PGF2α production can both contribute to 
persistent CL syndrome. Spontaneous or idiopathic persistent CL syndrome may also 
occur with normal uterine pathology. Persistent CL Syndrome progesterone 
concentrations are similar to the levels observed before the CL resurgence that occurs 
during pregnancy, with the concentration remaining constant approximately halfway 
between the levels recorded at day 8 and the end of luteolysis (Ginther and Santos, 2015).  
Eighty-five percent of anovulatory follicles in mares are hemorrhagic; the 
likelihood of anovulatory follicles may increase with age of mare as well as hormonal 
manipulation of the estrous cycle (Cuervo-Arango et al., 2009). When hemorrhagic 
anovulatory follicles are present, bleeding into the lumen of the dominant follicle occurs, 
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which is typically followed by eventual luteinization. Because of the anticoagulant 
factors found in equine follicular fluid, the blood does not clot as quickly. Once clotting 
begins, granulosa and theca cells enter the lumen, multiply, and then luteinize; in turn 
producing the luteinized anovulatory follicle which is responsible for progesterone 
production (Burden et al., 2015).  
A reported 15% of anovulatory follicles develop atresia, or become persistent 
anovulatory follicles. No significant hemorrhage occurs in the follicular lumen; the 
follicle does not luteinize and in turn does not produce progesterone (Burden et al., 
2015). Hemorrhagic anovulatory follicle formation may differ between studies as 
influenced by: breed of mares used, number of mares involved in the study, location of 
the experiment, timing and dosage of PGF2α treatments, as well as the extensity of 
reproductive management involved in the study (Burden et al., 2015).  
Following PGF2α treatment and subsequent luteolysis, a decrease in progesterone 
leads to an increase in LH at an earlier phase of follicular development, which may 
increase the probability of hemorrhagic anovulatory follicle development. Follicular 
growth and ovulation were not disrupted by increased and premature exposure to LH 
while fluid factors were altered, which could lead to lapses in maturation of the follicle or 
oocyte (Burden et al., 2015).  
Over a 17-year period, 319 combined estrous cycles from two mares were 
compared and analyzed. In 204 of the 319 cycles, luteolysis was induced with 
cloprostenol at varying doses (25 to 1,000 μg). Cloprostenol-manipulated cycles were 
more likely (P<0.000) to develop hemorrhagic anovulatory follicles than non-
manipulated cycles, with 25.1% total occurrence of hemorrhagic anovulatory follicles. In 
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both mares, the number of multiple dominant follicles, potentially leading to double 
ovulations, was higher (P < 0.00 and P= 0.004), respectively for the cloprostenol-treated 
cycles when compared to the naturally occurring cycles (Cuervo-Arango and Newcombe, 
2009). Small doses (8.75 μg) of cloprostenol have the same luteolytic effect as higher 
doses, with no difference in clinical response with the highest incidence recordings of 
hemorrhagic anovulatory follicles occurred when cloprostenol was given to mares at 
either 625 or 250 μg per dose (Newcombe et al., 2008).  
 
Physiological Effects of PGF2α Administration 
Common side effects associated with PGF2α treatment include sweating, 
abdominal cramping, and other behaviors associated with colic (Coffman and Pinto, 
2016). Listed behaviors, including abdominal cramping, diarrhea, and sweating may 
occur for as long as 20 minutes in approximately 10% of mares treated with PGF2α 
(McKinnon and Voss, 1993). Low dose (5 mg/mare) administration of the PGF2α analog 
Lutalyse may not induce the side effects associated with higher dose (10 mg/mare) 
administration in mares (Coffman and Pinto, 2016).  
Eight mares received luprostiol (3.75 mg IM), D-cloprostenol (22.5 μg IM), or 
saline on day 8 post-ovulation in an alternating order. In both luprostiol and cloprostenol 
treatment groups, plasma progesterone concentration decreased to the baseline level 
within two days following treatment (P <0.05). Salivary samples were collected to 
analyze cortisol levels, heart rate and heart rate variability were measured, skin 
temperature was recorded, behavior was monitored, and fecal output was recorded and 
scored for consistency. PGF2α treatment significantly increased the concentration of 
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salivary cortisol when measured 60 minutes after treatment (P < 0.001). Over time, heart 
rate decreased independently of treatment and no changes were recorded in heart rate 
variability post-treatment. Administration of PGF2α analogs, either cloprostenol or 
luprostiol, is an efficient way of inducing luteolysis with minimal significant side effects, 
aside from the increase in salivary cortisol levels (Kuhl et al., 2016b).  
When treated with cloprostenol (0.075 mg), 25 mares displayed significant (P 
<0.01) increase in intestinal motility. The increase in motility led to diarrhea on a short 
term basis, with symptoms subsiding within two hours following onset. Heart rate and 
respiratory rate were not significantly altered by administration of cloprostenol (P > 
0.05). Sweating and restlessness were also reported in 40-52% of mares involved in the 
study (Alcántara et al., 2005). 
Because the reproductive cycle of the mare and the timing of physiological events 
has such a large impact on the economic success of the equine industry, pregnancy rates 
are of utmost concern. After concerns arose that the use and administration of exogenous 
prostaglandins may lower conception may lead to lower pregnancy rates in mares, 
Metcalf and Thompson (2010) further researched the subject. The 2010 study concluded 
that the synchronization and induction of estrus using a prostaglandin analogue, 
cloprostenol, did not have a negative impact on pregnancy rate in treated mares (Metcalf 
and Thompson, 2010).  
 
Additional Uses of Exogenous Prostaglandins 
For mares with delayed uterine involution and endometritis, PGF2α may be given 
during the peri-ovulatory period due to its ecbolic effects, though this may lead to luteal 
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resurgence (Coffman and Pinto, 2016). In mares treated with PGF2α 24-72 hours post-
ovulation, no decrease in pregnancy rates occurred. During early embryonic growth and 
development, mares are capable of maintaining pregnancy with decreased progesterone 
concentrations (Newcombe and Cuervo-Arango, 2014). 
In mares, an increase in progesterone following a PGFM pulse has not been 
recorded. However, it is widely accepted that the equine primary  CL undergoes natural 
resurgence at day 35 of pregnancy. In pregnant mares, resurgence of the CL is linked to 
equine chorionic gonadotropin (eCG) from the endometrial cups and its luteotropic 
characteristics. As the size and vascularity of the CL increase, progesterone production 
also increases. During CL growth, partial resorption of the corpus hemorrhagicum will 
also occur (Ginther and Santos, 2015).  
The BAI HUI acupuncture point, in the sacral lumbar space, is commonly used in 
the treatment of ovarian conditions in veterinary acupuncture. A 1990s study was 
conducted to determine the efficacy of either low or micro doses of PGF2α, when 
administered at the BAI HUI acupuncture point. In this study, a micro dose (0.05 mg) 
was shown to be equally as effective (P<0.05) as the conventional dose (5.0 mg) when 
given to mares in the mid-luteal phase at inducing luteolysis. The BAI HUI acupuncture 
point provides an efficient pathway from administration to ovarian effect (Alvarenga et 
al., 1998).  
 
Other Protocols Utilized in Breeding Management 
Before PGF2α gained recognition as a natural luteolysin, uterine lavage using 
saline solution was often implemented for open mares showing signs of a prolonged 
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luteal phase in order to gain a return to estrus. This protocol then became a treatment for 
mares with a persistent CL. Additionally, intrauterine saline treatment 6 days after 
ovulation was shown to shorten the luteal phase of estrous in cycling mares (Coffman and 
Pinto, 2016).  
The efficacy of using estradiol to synchronize estrus compared to the use of 
estradiol and progesterone was evaluated. Mares in group 1 received 50 mg estradiol IM, 
and mares in group 2 received 50 mg estradiol in addition to 1.5 g sustained release 
progesterone. All mares included in both treatment groups were given 10 mg PGF2α IM 
10 days post-treatment. Examinations were performed on all mares via transrectal 
ultrasonography on days 1 and 10 post-treatment, then every 1 or 2 days thereafter in 
order to determine follicle size. After detection of a follicle larger than 30 mm and uterine 
edema, mares were given 0.5 mg histrelin, an analogue of GnRH. After administration of 
histrelin, mares were examined ultrasonographically every day until ovulation was 
detected. Group 1 mares did not display synchronization of estrus following treatment. 
However, mares in group 2 had a much more uniform and synchronized interval to 
ovulation of 20.4 + 1.5 days, with a range of 17-22 days. Researchers concluded that 
administration of sustained release estradiol and progesterone, followed by administration 
of PGF2α 10 days post-treatment, is effective in synchronization of estrus and ovulation, 
without daily injections being necessary (Sudderth et al., 2013).  
Equine follicle stimulating hormone (eFSH) is often incorporated into 
superovulation protocols. A 2010 study (Meyers-Brown et al., 2010) was conducted to 
determine whether or not administering varying doses of recombinant equine follicle 
stimulating hormone (reFSH) to mares would increase the number of ovulatory follicles 
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per cycle, and in turn increase the number of embryos recovered per mare. Because 
reFSH can be cloned and synthesized in reliable and consistent quantities, its use over 
eFSH is much preferred. As part of the experimental protocol, treatment groups were 
given varying doses of eFSH, reFSH, and a combination thereof. The largest number of 
ovulations was recorded for the group receiving 12.5 mg eFSH, 0.5 mg reFSH, and 0.65 
mg reFSH. The treatment group receiving eFSH and 0.65 mg reFSH had the highest 
recorded number of embryos recovered per flush. Also noted in the conclusions was the 
similar embryo per ovulation rates between all treatment groups, including the control 
group. After data analysis, researchers concluded that administration of reFSH is just as 
effective as eFSH, when given to increase the number of follicles greater than 35 mm, 
ovulation rates, and the number of embryos recovered per flush (Meyers-Brown et al., 
2010).  
In order to simulate a natural PGFM pulse that occurs during luteolysis, oxytocin 
(OT) may be administered on day 13 post-ovulation to induce the PGFM pulse. Five 
different OT doses (1-10 IU/mare) were used for bolus treatment in the mares. Mares that 
received 1.25, 2.5, and 5 IU/100 kg displayed the largest decrease in progesterone within 
8 hours of treatment (P < 0.05). Although cyclooxygenase inhibitor treatment with 
flunixin meglumine decreased progesterone concentration (P < 0.008), treatment 2 hours 
prior to OT administration did not inhibit OT-induced PGFM pulses and the subsequent 
decrease in progesterone. A 2 hour OT infusion was sufficient in the study to induce the 
PGFM pulse, however the pulse was not stimulated by a single bolus OT treatment. The 
OT-stimulated PGFM pulse caused a decrease in progesterone, which was not inhibited 
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by flunixin meglumine treatment. In turn, OT has a role in luteolysis in mares, as well as 
other species (Santos et al., 2015).   
Human chorionic gonadotropin (hCG) dosage rate varies between 1500 to 4000 
IU, which  an be given either IV or IM. Typical administration of hCG occurs after a 
follicle measuring 30 mm or larger is detected. Lower synchronization rates may occur 
when hCG is administered on days 1-3 of estrus. Additionally, administration of hCG 
may reduce the length of estrous in cycling mares (McKinnon and Voss, 1993).  
In the presence of a 35 mm or larger follicle, hCG has been shown to induce 
ovulation within 48 hours following treatment. Because hCG is a glycoprotein, antibodies 
may develop over the course of repeated treatments, leading to a decrease in the efficacy 
of hCG-induced ovulation (Berezowski et al., 2004). Gonadotropin releasing hormone 
has been shown to double plasma LH concentrations following administration. GnRH can 
be given in order to induce the secretion of FSH and LH, and in turn inducing follicular 
growth and development, CL maturation, and ovulation. GnRH may also serve as a 
nonantigenic substitute for the administration of hCG to induce ovulation.  
Human chorionic gonadotropin is commonly used in Europe for the induction of 
ovulation in mares. Mares are often used several times throughout each breeding season; 
antibodies against hCG may develop, in turn reducing the efficacy of the treatment 
(Newcombe and Cuervo-Arango, 2016). Desorelin does not increase production of hCG 
antibodies, but the interovulatory interval for each cycle may increase. Deslorelin is also 
less cost efficient per mare when compared to hCG. Suprefact©, (Sanofi; 1 mg/mL), is a 
buserelin compound used in human medicine and experimentally used in mares. A large 
(5.5 mL), single dose of buserelin was shown to be just as effective at inducing ovulation 
 24 
within 48 hours of treatment as hCG. When comparing mares treated with buserelin and 
hCG, a larger number of mares (P<0.05) ovulated when given buserelin than hCG. 
Because buserelin is effective when given as a single dose and is relatively inexpensive, 
its use provides an alternative to multi-dose hCG ovulation induction (Newcombe and 
Cuervo-Arango, 2016). Ovulation may be induced efficiently via hCG administration 
when given after estrus is induced with luprostiol (Kuhl et al., 2016a). 
In 1999, deslorelin (Ovuplant, Fort Dodge Animal Health, Overland Park, KS), a 
GnRH agonist, was approved for use in mares when administered as a subcutaneous 
controlled-release implant. When compared to hCG, repeated treatment with GnRH has 
not been shown to decrease efficacy of ovulation induction. In mares with a 30 mm or 
larger follicle, 88% of mares were shown to ovulate within the 48 hours following 
treatment when induced with Ovuplant; however Ovuplant is not available for use in 
mares in the United States (Berezowski et al., 2004).  
Although Ovuplant is not available for use, an injectable deslorelin analog, 
Sucromate ™ (Thorn BioScience, Lexington, KY) has been approved by the FDA for use 
in the United States. A 2012 study compared the efficacy of delsorelin to induce 
ovulation in mares when compared to hCG. After detection of a follicle measuring 35 
mm or larger, 1.0 mL of Sucromate was administered intramuscularly. Approximately 
89% of mares ovulated without 48 hours following treatment, a rate similar to that seen 
following administration of hCG. The study concluded that Sucromate, injectable 
deslorelin, is an effective method of inducing ovulation in mares (Ferris et al., 2012).  
Although less common, fractionated coconut oil can be implemented in 
intrauterine infusion protocols for mares. Plant oil infusion has been shown to be a safe, 
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reversible, and inexpensive method of lengthening the luteal phase of the estrous cycle 
when administered to mares on day 10 of the cycle. Diel de Amorim et al. (2016) 
hypothesized that administration of intrauterine coconut oil infusion would lead to higher 
serum progesterone levels at the time of luteolysis when compared to untreated mares. 
For the study, half of the mares (n=5) were administered 1.0 mL fractionated coconut oil 
infused into the uterus using an artificial semination pipette on day 10 of the estrous 
cycle; the remaining mares (n=5) were given 0.5 mL fractionated coconut oil infused into 
the uterus using an embryo transfer gun on day 10 of the estrous cycle. Intrauterine 
administration of 1.0 mL fractionated coconut oil did not lengthen the luteal phase in the 
treated mares, and lowered diestrus progesterone levels (P<0.05). In a 2013 preliminary 
study comparing sesame, coconut, and fractionated coconut oils, the same results were 
found; progesterone levels decreased at the time of luteolysis, with a faster return to 
estrus (Diel de Armorim et al., 2016).  
Flunixin meglumine (FM), a PGF2α inhibitor, can be administered in order to 
analyze the occurrence of prolonged luteal activity in treated mares. As part of Santos et 
al.’s study (2013), FM was administered every 8 hours at 1.0 mg/kg body weight on days 
14-16.7. PGF2α metabolite concentration over an 8 hour time period was lower in the 
mares treated with FM on day 14 post-ovulation, compared to the untreated mares. The 
interval from ovulation to a decrease in progesterone and the end of luteolysis (P4<1 
ng/mL) was prolonged by approximately 1 day in the mares treated with FM. This study 
confirmed that PGF2α synthesis inhibition effects luteolysis, and if inhibition occurs at the 
time luteolysis is expected, prolonged luteal activity may be present (Santos et al., 2013).  
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Figure 1. Stages of the estrous cycle (Mottershead, 2001).  
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Figure 2. Endocrinology of the estrous cycle (Mottershead, 2001).  
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Figure 3. Plasma progesterone levels (ng/mL) in pregnant vs non-pregnant mares 
(McKinnon and Voss, 1993) 
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MATERIALS AND METHODS 
 
IACUC Compliance 
This project was funded by the USDA NLGCA Capacity Building Grant and 
approved by IACUC Protocol 15-025.0-B. Research was conducted at the Missouri State 
University Darr Agriculture Center in Springfield, Missouri. Research began in May 
2017 and concluded in July 2017. Eleven Quarter Horse mares (468- 572 kg, 7-23 years 
old) were used for the study. 
 
Experimental Design and Procedures 
Mares were teased using a teaser stallion, and teasing scores (T0-T4) were 
assessed daily. A description of criteria for each teasing score is as follows: 
0 Mare shows no signs of receptivity; possibly some aggression toward the 
stallion- striking, kicking, squealing, etc. 
1 No aggression toward the stallion. 
2 Some interest; mare may approach the stallion and exhibit some winking 
of the vulva and tail raising. 
3 More interest, tail raising, squatting, urination.  
4 Intense interest; turns hindquarters toward the stallion with continuous 
winking and frequent urination. 
(Coleman and Powell, 2004) 
 
 Once a T3 teasing score was detected, rectal palpation and ultrasound were both 
performed. A digital ultrasound display and transrectal probe were used in order to 
 30 
perform ultrasound, and follicular diameter was measured (mm) during each 
examination. Individual record books were utilized for each mare in order to record 
teasing scores as well as follicular growth and location (right or left ovary) of each 
follicle. When an ovarian follicle measured 30 mm or larger, mares were examined daily, 
including rectal palpation, ultrasound, and measurement of follicles, until ovulation was 
detected. 
 In a crossover design, each mare was subjected to all treatments. Mares were 
assigned to one of three treatment groups. Treatment protocols were as follows: treatment 
1- PGF2α administered once on day 6 post-ovulation; treatment 2- PGF2α administered 
twice daily on days 0, 1, and 2, then once on days 3 and 4 post-ovulation; treatment 3- 
PGF2α administered twice daily on day 2, then once on days 3 and 4 post-ovulation. 
Dinoprost tromethamine (Lutalyse ®) was administered at a dosage rate of 1 mg/45.5 kg 
body weight, and concentrated in a 5 mg/mL solution. Lutalyse was administered IM to 
each mare for each dose of the assigned treatment. To ensure that each mare received a 
full 1.0 mL of Lutalyse for each dose of each treatment, 1.1 mL was administered per 
injection. Treatment 1 was used as a control protocol; a single injection of PGF2α is 
typically administered to induce luteolysis. Treatments 2 and 3 were included in the study 
to repeat the protocols of a previous studies utilizing higher dosage rates of Lutalyse 
(Coffman et al., 2014; Pinto et al., 2014).  
In order to track fluctuations in P4 levels for each mare, blood samples were 
collected using jugular venipuncture on days 3 and 6 post-ovulation. Blood was collected 
using 6.0 mL syringes with 18.0 gauge needles. Samples were transferred to 10 mL BD 
Vacutainer® vials, then set in test-tube rack in order to clot, for approximately ten 
 31 
minutes. Once coagulation occurred, vials were centrifuged for five minutes in order to 
separate serum from the clot. Serum was removed from the vials using 3 mL disposable 
pipettes, and placed in 1.5 mL microcentrifuge vials. Each 1.5 mL vial with serum was 
labeled with the date and the identifying number of the horse, then frozen. Progesterone 
ELISA kits ADI-900-011 and ADI-901-011 (Enzo Life Sciences) were used to analyze 
samples by Northcutt Laboratories in Middletown, Missouri. The assay was run at a 
dilution rate of 1 to 125, 1 to 250, or 1 to 400 in order to reach a 50% binding rate for 
each sample. Results were recorded in picograms per milliliter then converted to 
nanograms per milliliter for analysis in this study. 
 
Statistics 
Minitab 17 (Minitab Inc., State College, PA) software was used for data analysis, 
with significant difference set at p = 0.05. One-way ANOVA and the Tukey Method 
pairwise comparisons were used in order to analyze the intervals from ovulation to 
ovulation and treatment to ovulation between treatment groups.  
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RESULTS AND DISCUSSION 
 
Data Analysis 
The age and approximate weight of mares used in the study were recorded in T1. 
The order of treatments received for each mare in the study were random, and recorded in 
T2. Mean intervals from ovulation to ovulation for treatments 1, 2, and 3 were 14.8 d ± 
3.1, 12.9 d ± 6.3 d and 14.3 d ± 1.4 respectively, and recorded in T3. Mean intervals from 
first day of treatment to ovulation for treatments 1, 2, and 3 were 9.8 d ± 2.0, 12.9 d ± 
6.3, and 12.6 d ±1.7, and recorded in T4. ANOVA analysis of these variables revealed no 
significant differences (p>0.05).  
Mean intervals from ovulation to the detection of a 30+mm follicle for treatments 
1, 2, and 3 were 13.2 d ± 2.2, 9.2 d ± 3.0, and 12.0 d ± 2.2 respectively, and recorded in 
T5. Mean intervals from the first day of treatment to the detection of a 30+ mm follicle 
for treatments 1, 2, and 3 were 8.1 d ± 1.1, 9.5 d ± 2.7, and 10.3 d ± 1.7 respectively, and 
recorded in T6. Mean intervals from ovulation to the display of estrus (teasing score ≥ 
T3) for treatments 1, 2, and 3 were 10.6 d ± 4.4, 6.9 d ± 2.6, and 10.3 d ± 6.8 
respectively, and recorded in T7. Mean intervals from the first day of treatment to the 
display of estrus (teasing score ≥ T3) for treatments 1, 2, and 3 were 5.9 d ± 3.6, 8.1 d ± 
5.2, and 6.0 d ± 3.9 respectively, and recorded in T8.  
Mean intervals from ovulation to ovulation for treatments 1, 2, and 3 with outliers 
removed (n=1) from analysis were 14.8 d ± 3.1, 11.1 d ± 3.1, and 14.3 d ± 1.4 
respectively. Under Tukey Method pairwise comparison, treatment 2 was significantly 
different from treatments 1 and 3 (p= 0.013). Mean intervals from first day of treatment 
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to ovulation for treatments 1, 2, and 3 with outliers removed from analysis were 9.8 d ± 
2.0, 11.1 d ± 3.1, and 12.6 d ± 1.7 respectively. Treatments 2 and 3 were significantly 
different from treatment 1, though not significantly different from each other (p= 0.052).   
Mean plasma progesterone levels on day 3 post-ovulation for treatments 1, 2, and 
3 were 6.0 d ± 2.5, 4.5 d ± 1.9, and 6.4 d ± 1.6 respectively, and recorded in T9. Mean 
plasma progesterone levels on day 6 post-ovulation for treatments 1, 2, and 3 were 10.9 d 
± 10.1, 3.9 d ± 2.0, and 3.9 d ± 1.9 respectively, and recorded in T10. Plasma 
progesterone levels were not statistically difference between treatments from day 3 to day 
6 post-ovulation. However, progesterone levels numerically increased within treatment 1 
from day 3 to day 6 post-ovulation. Progesterone levels decreased between days 3 and 6 
post- ovulation for treatments 2 and 3.  
 
Data Limitations 
Statistical outliers may have contributed to a lack of significance in results. When 
One-way ANOVA and Tukey Method analysis were performed removing statistical 
outliers, some results of the study became statistically significant. 
Plasma progesterone immuno-assay test levels were not all attained at the desired 
50% binding rate. Values recorded at less than 50% binding may be less accurate, and 
may have contributed to statistical skew and lack of significance.   
 
Discussion 
Although results were not significantly different, these findings agree with 
previous studies (Coffman et al., 2014; Pinto et al., 2014) utilizing a dose of 10 mg 
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dinoprost tromethamine. On treatment 2, one mare displayed estrus and maintained a 
follicle greater than 30 mm for 13 days, and had an intra-ovulatory interval of 29 days. 
On treatment 3, one mare failed to return to estrus or develop a dominant follicle 
measuring larger than 30 mm. Statistical outliers as described may have contributed to a 
lack of significance in statistical analysis; however results of treatment 2 became 
significantly different from treatments 1 and 3 with outliers removed.  
Previous studies have utilized administration of hCG following PGF2α to ensure 
timely ovulations. Mares develop antibodies against hCG with repeated treatment, in turn 
decreasing efficacy rates. Because mares were used in a crossover design with three 
subsequent estrous cycles, hCG was not administered to mares following each PGF2α 
protocol.  If hCG or Delsorelin had been administered to mares along with PGF2α for 
each treatment protocol, evaluation of the efficacy of low-dose serial administration of 
PGF2α might have been compromised.  
Mares in this study were characterized by a wide range in age, as seen in Table 1. 
A more uniform age range for mares used in subsequent studies may provide more 
consistent results, potentially with statistical significance. In this study, maiden mares 
were used alongside broodmares. Increasing uniformity of mares used by decreasing the 
range in ages may have improved results of the study. Additionally, a larger sample size 
would have most likely increased the consistency of results seen in the study.  
Plasma progesterone levels were analyzed in order to track changes throughout 
the estrous cycle for each mare for each given treatment. Also, plasma progesterone 
levels were evaluated as a measure of luteal tissue development for each treatment. If 
serial low-dose administration of PGF2α had prevented luteal tissue development during 
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the early diestrus period, progesterone levels should have verified the absence of a 
functional CL. However, plasma progesterone results were not significantly different 
among treatment groups. Most serum samples were run at varying dilutions in attempts to 
reach a minimum 50% binding rate for each sample. However, not all samples were re-
run to obtain a higher binding rate, as opposed to other samples which were re-run two 
and three times. With binding rates as low as 11.1% and as high as 91.2%, a wide range 
of plasma progesterone levels were recorded. Because of such a wide range in recorded 
results, statistical analysis of progesterone levels showed no significance. If serum 
samples had reached a more uniform range of percent antibody binding rate, results may 
have become significant and supported the hypothesized prevention of luteal 
development.  
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Table 1. Ages (years) and weights (kg) of Quarter Horse mares treated with serial 
injections of PGF2α 
Mare Age Weight 
1 22 558 
2 6 457 
3 22 564 
4 6 395 
5 18 518 
6 10 498 
7 15 505 
8 12 573 
9 15 493 
10 24 470 
11 12 550 
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Table 2. Order of treatment protocol received for mares treated with serial injections of 
PGF2α 
Mare Treatment 1* Treatment 2** Treatment 3*** 
1 A B C 
2 C A B 
3 C A B 
4 A C B 
5 C A B 
6 B A C 
7 B C A 
8 C A B 
9 C B A 
10 B A C 
11 A B C 
A- First treatment 
B- Second treatment 
C- Third treatment 
*- One injection of PGF2α 6 d post-ovulation 
**- Injections of PGF2α twice daily on d 0,1, and 2, then once daily on d 3 and 4 post-
ovulation 
***- Injections of PGF2α twice daily on d 2, then once daily on d 3 and 4 post-ovulation 
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Table 3.  Mean number of days recorded from ovulation to ovulation for mares treated 
with serial PGF2α injections, by treatment 
a- One injection of PGF2α 6 d post-ovulation 
b- Injections of PGF2α twice daily on d 0,1, and 2, then once daily on d 3 and 4 post-
ovulation 
c- Injections of PGF2α twice daily on d 2, then once daily on d 3 and 4 post-ovulation 
 
 
 
Table 4.  Mean number of days recorded from first day of treatment to ovulation for 
mares treated with serial injections of PGF2α, by treatment 
Treatment Mean SD Range  Covariance   
1a 9.8 2.0 5-12  3.76   
2b 12.9 6.3 4-29  36.29   
3c 12.6 1.7 10-16  2.47   
a- One injection of PGF2α 6 d post-ovulation 
b- Injections of PGF2α twice daily on d 0,1, and 2, then once daily on d 3 and 4 post-
ovulation 
c- Injections of PGF2α twice daily on d 2, then once daily on d 3 and 4 post-ovulation 
 
 
 
Treatment Mean SD Range  Covariance   
1a 14.8 3.1 9-18  8.76   
2b 12.9 6.3 4-29  36.29   
3c 14.3 1.4 12-17  1.78   
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Table 5. Mean number of days recorded from ovulation to detection of a 30+ mm follicle 
for mares treated with serial injections of PGF2α, by treatment 
Treatment Mean SD Range  Covariance   
1a 13.2 2.2 9-16  4.17   
2b 9.2 3.0 3-13  8.16   
3c 12.0 2.0 9-15  3.56   
a- One injection of PGF2α 6 d post-ovulation 
b- Injections of PGF2α twice daily on d 0,1, and 2, then once daily on d 3 and 4 post-
ovulation 
c- Injections of PGF2α twice daily on d 2, then once daily on d 3 and 4 post-ovulation 
 
 
 
 
Table 6. Mean number of days recorded from first day of treatment to detection of a 30+ 
mm follicle for mares treated with serial injections of PGF2α, by treatment 
Treatment Mean SD Range  Covariance   
1a 8.1 1.1 7-10  1.11   
2b 9.5 2.7 3-13  6.65   
3c 10.3 1.7 7-13  2.44   
a- One injection of PGF2α 6 d post-ovulation 
b- Injections of PGF2α twice daily on d 0,1, and 2, then once daily on d 3 and 4 post-
ovulation 
c- Injections of PGF2α twice daily on d 2, then once daily on d 3 and 4 post-ovulation 
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Table 7. Mean number of days recorded from ovulation to detection of the onset of estrus 
(teasing score ≥ T3) for mares treated with serial injections of PGF2α, by treatment 
Treatment Mean SD Range  Covariance   
1a 10.6 4.4 1-16  17.64   
2b 6.9 2.6 3-11  5.86   
3c 10.3 6.8 4-24  39.35   
a- One injection of PGF2α 6 d post-ovulation 
b- Injections of PGF2α twice daily on d 0,1, and 2, then once daily on d 3 and 4 post-
ovulation 
c- Injections of PGF2α twice daily on d 2, then once daily on d 3 and 4 post-ovulation 
 
 
 
Table 8. Mean number of days recorded from first day of treatment to detection of the 
onset of estrus (teasing score ≥ T3) for mares treated with serial injections of PGF2α, by 
treatment 
Treatment Mean SD Range  Covariance   
1a 5.9 3.6 0-12  11.49   
2b 8.1 5.2 3-20  23.88   
3c 6.0 3.9 1-12  12.67   
a- One injection of PGF2α 6 d post-ovulation 
b- Injections of PGF2α twice daily on d 0,1, and 2, then once daily on d 3 and 4 post-
ovulation 
c- Injections of PGF2α twice daily on d 2, then once daily on d 3 and 4 post-ovulation 
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Table 9.  Mean plasma progesterone concentrations on day 3 post-ovulation for mares 
treated with serial injections of PGF2α, by treatment (ng/mL) 
Treatment Mean SD Range  Covariance   
1a 6.0 2.5 3.3-9.1  4.57   
2b 4.5 1.9 2.6-7.0  3.07   
3c 6.4 1.6 3.7-8.9  2.39   
a- One injection of PGF2α 6 d post-ovulation 
b- Injections of PGF2α twice daily on d 0,1, and 2, then once daily on d 3 and 4 post-
ovulation 
c- Injections of PGF2α twice daily on d 2, then once daily on d 3 and 4 post-ovulation 
 
 
Table 10.  Mean plasma progesterone concentrations on day 6 post-ovulation for mares 
treated with serial injections of PGF2α, by treatment (ng/mL) 
Treatment Mean SD Range  Covariance   
1a 10.9 10.1 2.7-34.2  4.62   
2b 3.9 2.0 1.6-7.0  3.33   
3c 3.9 1.9 1.8-6.2  7.29   
a- One injection of PGF2α 6 d post-ovulation 
b- Injections of PGF2α twice daily on d 0,1, and 2, then once daily on d 3 and 4 post-
ovulation 
c- Injections of PGF2α twice daily on d 2, then once daily on d 3 and 4 post-ovulation 
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CONCLUSIONS  
 
In this study, no significant difference was shown between single and multiple- 
dose PGF2α treatment protocols used to prevent luteal development and shorten the 
interval to ovulation in cycling mares. However, low-dose administration of PGF2α may 
provide an alternative to the 10.0 mg dose normally given. Low-dose administration of 
PGF2α during the early diestrus period of the estrous cycle has the potential to improve 
the efficiency of breeding programs in terms of total injections administered and intensity 
of the protocol.  
Previous studies implementing a single-dose treatment as a control have 
administered PGF2α as a single injection between days 5 and 10 post-ovulation, during 
the mid-diestrus period. However, the CL has been shown to be responsive to PGF2α 
when the CL reaches maturity at 5 days post-ovulation; therefore the single dose 
treatment used in this study administered one injection of PGF2α on day 6 post-ovulation.  
Results of the study were similar to previous studies implementing the protocol 
used for Treatment 3. Treatment 3 could be utilized by owners or breeding facility 
professionals if an ovulation goes undetected. However, if the exact date of ovulation is 
unknown, treatment with serial PGF2α may not be as effective at shortening the interval to 
ovulation when the treatment is started a few days later.  In terms of efficacy, PGF2α 
treatment is most successful when ovulation can be tracked and recorded, and a treatment 
protocol implemented accordingly.   
Although overall results were not significant, the statistical analysis with outliers 
removed supports the hypothesis that serial administration of PGF2α may prevent luteal 
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development and may provide a means of faster manipulation of the mare in order to 
successfully complete time-sensitive breedings and embryo transfer programs.   
Breeding facilities often charge owners for individual daily expenses of 
management- boarding, feed and supplements, palpation, ultrasound, injections, 
insemination, pregnancy checks, and more. With high costs associated with long-term 
boarding at breeding facilities, shortening the interval to ovulation by even 2 days could 
provide financial savings for equine owners. Example costs associated with daily mare 
care and management at a breeding facility are as follows: 
Description Cost 
Dry Mare Board $12.00-20.00/day 
Dry Mare Board, Under Lights $17.00-20.00/day 
Private Care Board $20.00-29.00/day 
Special Care Board $20.00-29.00/day 
Palpation $15.00-16.00 each 
Palpation and Breeding $10.00-25.00-each 
Ultrasound $40.00-65.00/breeding season 
Progesterone Assay $30.00-35.00 each 
Regumate $3.50-6.00/day 
(Granada Farms, 2017; Lazy E Ranch, 2017; Oswood Stallion Station, 2017) 
 
 Lutalyse, when administered at 1.1 mL per dose, is approximately $0.64 per 
injection. With minimal daily mare care starting approximately $17 per day, utilization of 
a low-dose serial PGF2α treatment protocol may provide significant savings. At a low-
cost, serial administration of PGF2α may provide a relatively inexpensive method of 
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shortening the interval to ovulation. The estimated costs per treatment protocol is 
described as follows: 
Description Cost 
1.0 mL (5.0 mg) Lutalyse $0.57-0.67/dose 
2.0 mL (10.0 mg) Lutalyse $1.15-1.36/dose 
Treatment 1 Protocola $0.57-0.67/mare 
Treatment 2 Protocolb $4.56-5.36/mare 
Treatment 3 Protocolc $2.28-2.68/mare 
(Valley Vet Supply, 2017) 
a- One injection of PGF2α 6 d post-ovulation 
b- Injections of PGF2α twice daily on d 0,1, and 2, then once daily on d 3 and 4 post-
ovulation 
c- Injections of PGF2α twice daily on d 2, then once daily on d 3 and 4 post-ovulation 
Further research is needed to determine the effects of serial low-dose 
administration of a PGF2α analog on the interval to ovulation in mares.  
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